Association of Systemic Collagen Type IV Formation with Survival among Patients Undergoing Hemodialysis

Diana J. Leeming¹, Morten A. Karsdal¹, Lars M. Rasmussen², Alexandra Scholze³, Martin Tepel³

¹ Nordic Bioscience, Herlev, Denmark, ² Odense University Hospital, Department of Clinical Biochemistry and Pharmacology, Odense, Denmark, ³ Odense University Hospital, Department of Nephrology, Institute for Molecular Medicine, Cardiovascular and Renal Research, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

Abstract

Objective: The 7S domain of collagen type IV (P4NP_7S) assessed in plasma represents systemic collagen type IV formation. The objective of the study was to investigate the association of systemic collagen type IV formation with survival among patients undergoing hemodialysis.

Methods: We performed an observational cohort study of 371 hemodialysis patients. Plasma P4NP_7S was analyzed using a specific enzyme-linked immunosorbent assay detecting the amino-terminal propeptide of type IV procollagen. Association between categories of plasma P4NP_7S concentrations and survival was initially assessed by Kaplan–Meier analysis, then in an adjusted Cox model.

Results: For hemodialysis patients in the highest category of systemic collagen type IV formation, i.e. plasma P4NP_7S concentrations more than 775 pg/L, an increased risk for death was observed (highest P4NP_7S category vs all other categories, hazard ratio, 1.934; 95% confidence interval, 1.139 to 3.285). Survival analysis showed an increased risk of death in the highest P4NP_7S category compared to the other categories (Chi square 6.903; P = 0.032). Median survival was only 105 days in the highest P4NP_7S category whereas it was 629 days in the medium category, and 905 days in the lowest category. Multivariable-adjusted Cox regression showed increased odds for death with higher age and higher P4NP_7S categories. Systemic collagen type IV formation was associated with plasma concentrations of the collagen IV degradation product C4M (Spearman r = 0.764; P < 0.0001) confirming extracellular matrix turnover.

Conclusion: Among hemodialysis patients elevated systemic collagen type IV formation suggesting accelerating systemic fibrosis was associated with increased risk of death.

Introduction

Excess mortality in patients with chronic kidney disease compared to the general population is still an important problem which needs to be addressed [1–3]. Using data from the European Renal Association–European Dialysis and Transplant Association registry, DeJager et al. reported that dialysis patients have a generally increased risk of death compared to the general population (overall all-cause mortality rate, 192 per 1000 person-years vs 12 per 1000 person-years) [4]. Recent investigations indicated that systemic fibrosis may contribute to excess mortality in patients with chronic kidney disease [5]. Increased inflammation, oxidative stress and increased levels of transforming growth factor-β are commonly observed in patients and animal models with chronic kidney disease [6–8]. In chronic kidney disease an increased inflammatory response triggers a fibrotic reaction of the connective tissue in several organs mainly characterized by an increased production of extracellular matrix components and mesenchymal cell proliferation, migration and accumulation [9]. Enhanced fibrosis in patients with chronic kidney disease is a systemic event. For example, key features of uremic cardiomyopathy include enhanced cardiac fibrosis, left ventricular hypertrophy, and systolic dysfunction [10–12].

Collagen type IV is primarily located in basement membranes of heart, lung, vessels, liver, and kidney tissue. Several studies have shown elevated expression of collagen type IV in the basement membrane from patients with chronic kidney disease [13–15]. Pathology studies indicate that the extent of collagen type IV deposition correlated with the severity of interstitial histological abnormalities [16]. Furthermore, recent clinical investigations indicate that increased urinary collagen type IV excretion is associated with progression of kidney function decline in diabetes mellitus type 2 and diabetes mellitus type 1 patients [17,18].

During collagen turnover proteins are degraded which results in the release of unique and specific fragments into the circulation. The amino-terminal propeptide of type IV procollagen (P4NP) is an extension peptide of the procollagen type IV, which is cleaved off stoichiometrically during conversion from type IV procollagen.
to type IV collagen. After cleavage by proteases the fragment P4NP_7S is liberated into the systemic level and can be assessed in plasma [19]. The molecular weight of the P4NP_7S fragment is approximately 13,670 daltons. P4NP_7S represents systemic collagen type IV formation, including synthesis and deposition as well as altered degradation and elimination. Human plasma P4NP_7S concentrations have already been described as a marker for systemic fibrosis [13-20], nevertheless using techniques that employ polyclonal antibodies in contrast to the present assay that uses a monoclonal antibody and thus is specific for a single epitope in the P4NP_7S domain. Furthermore, no data are available whether the extent of systemic fibrosis may be associated with mortality in hemodialysis patients. In the present study we investigated the association of systemic collagen type IV formation with survival among patients undergoing hemodialysis.

Methods

Ethics Statement
All research involving human participants was approved by the local ethics committee (Ethikkommission Free University Berlin, Reference numbers: ek.211-19, ek.Tc.2.02). Informed consent was obtained and all clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all patients before entry into the study.

Study population
To determine associations among plasma soluble 7S domain of collagen type IV (P4NP_7S) concentrations and mortality in hemodialysis patients we performed a cohort study in 371 hemodialysis patients which were followed up for 5 years. Our eligibility criteria were broad and included all adult patients on hemodialysis treatment due to end-stage chronic kidney disease stage 5 and presence of informed consent. Exclusion criteria were absence of informed consent. Data on time since initiation of dialysis at inclusion and duration of hemodialysis treatment per session were obtained. All patients were routinely dialedyzed for 4 to 5 hours three times weekly using biocompatible synthetic polysulfone membranes with no dialyzer reuse. None of the patients had hemodiafiltration. Blood flow rates were 250 to 300 mL/min, dialysate flow rates were 500 mL/min, and dialysate sodium ranged from 135 mmol/L to 145 mmol/L. Anticoagulation during hemodialysis was performed using heparin. No patient had argatroban, danaparoid, nor citrate anticoagulation. A history of dialysis at inclusion and duration of hemodialysis treatment per session were obtained. All patients were routinely dialedyzed for 4 to 5 hours three times weekly using biocompatible synthetic polysulfone membranes with no dialyzer reuse. None of the patients had hemodiafiltration. Blood flow rates were 250 to 300 mL/min, dialysate flow rates were 500 mL/min, and dialysate sodium ranged from 135 mmol/L to 145 mmol/L. Anticoagulation during hemodialysis was performed using heparin. No patient had argatroban, danaparoid, nor citrate anticoagulation. A history of gadolinium exposure had not been recorded. Blood pressure was measured predialysis in patients in a recumbent position. Predialysis blood samples were taken at study entry. Blood was collected immediately before the start of the hemodialysis session.

Clinical and laboratory data included age, gender, medications (use of angiotensin-converting-enzyme inhibitors, β-blockers, calcium channel blockers, and erythropoietin), body mass index (calculated as weight in kilograms divided by height in meters squared), systolic and diastolic blood pressure, serum albumin, serum urea, serum calcium, serum potassium, serum phosphorus, parathyroid hormone, cholesterol, and Low-Density-Lipoprotein cholesterol.

182 patients (49%) died during the follow up. The causes of death were classified as cardiovascular, infection, cancer, or unknown.

ELISA protocols
Plasma P4NP_7S concentrations were measured using a specific ELISA targeting the 7S domain of type IV collagen as developed by our group [19]. Briefly, the monoclonal antibody, which was specifically raised against the synthetic peptide derived from a unique site in the 7S domain of collagen type IV, Biotin-CGG-PGEILGHVPG, was purified from collected culture supernatants using HiTrap affinity columns (GE Healthcare Life Science, Little Chalfont, Buckinghamshire, UK) and labeled with horseradish peroxidase (HRP) using Lightning-Link-HRP-Conjugation-Kit (Innova Biosciences, Babraham, Cambridge, UK), according to the manufacturer’s instructions. The calibrators were dissolved in phosphate buffered saline (PBS) and used in the assay in this matrix. This antibody does not show any cross reactivity with other collagen structures. The P4NP_7S competitive ELISA procedure was as follows: A 96-well streptavidin-coated enzyme-linked immunosorbsent assay plate from Roche (Roche Diagnostics; Hvidovre; Denmark), was coated with the biotinylated specific P4NP_7S peptide against which the antibody had been raised (Biotin-CGG-PGEILGHVPG) dissolved in assay buffer (50 mmol/L 1,3,5-Tris(4-carboxyphenyl)benzene, pH 7.4), incubated for 30 min at 20°C in the dark and subsequently washed in washing buffer (20 mmol/L Tris, 50 mmol/L NaCl, pH 7.2). Thereafter 20 μl of peptide calibrator or sample were added to be appropriate wells, followed by 100 μl of HRP-conjugated monoclonal antibody NB102-1E5 and the plate was incubated for 1 hour at 20°C and in the dark. Finally, 100 μl tetramethylbenzidine (Kem-En-Tec Nordic; Taastrup; Denmark) was added, the plate was incubated for 15 min at 20°C, and in order to stop the reaction, 100 μl of stopping solution (1% H2SO4) was added and the plate was analyzed in the ELISA reader at 450 nm with 650 nm as the reference [MultiDevices, SpectraMax M; Sunnyvale; CA; USA]. A calibration curve was plotted using a 4-parametric mathematical fit model and the concentration of each sample was determined. The assay detection range was 8 to 500 pg/L, the intra-assay variation was 9.7%, and the inter-assay variation was 11.7%. Additional experiments confirmed that determinations using this ELISA did not show any interferences with biotin, immunoglobulins or lipid fractions. The molecular weight of the P4NP_7S fragment is approximately 13,670 daltons. It may not pass commonly used hemodialysis membranes. However, it is unknown whether smaller fragments may occur in vivo.

Similarly, plasma concentrations of the collagen type IV matrix metalloproteinase (MMP) degradation product C4M were measured using a specific ELISA targeting the MMP-2/-9 degraded type IV collagen. The monoclonal antibody used in our assay was developed to selectively recognize this MMP-2 and -9 cleavage site. The assay detection range was 1 to 100 pg/L, the intra-assay variation was 4.8%, and the inter-assay variation was 12.1%.

Statistics
Continuous variables were expressed as median with interquartile range and compared with non-parametric Mann-Whitney test or non-parametric Kruskal-Wallis test and Dunn’s multiple comparison post-hoc test where appropriate. Associations between variables were tested using non-parametric Spearman correlation. Categorical variables were expressed as proportions and compared with the Chi-square test. Time-to-event analyses were performed using the Kaplan-Meier method. Comparisons of survival curves were performed using the log-rank (Mantel-Cox) test. Data were initially stratified by deciles, then they were stratified into categories with the lowest category being the lowest plasma P4NP_7S decile the medium category being all intermediate plasma P4NP_7S deciles, and the highest category being the highest plasma P4NP_7S decile. Unadjusted and multivariable-adjusted survival analyses were performed using the proportional hazards regression model.
Multivariable models were constructed with backward variable selection, using $P < 0.05$ for variable retention. 46 patients (12%) underwent kidney transplantation during the follow up. These patients were censored on the day of transplantation.

All hypothesis tests were 2-sided, with statistical significance defined as having a $P$ value of less than 0.05. Statistical analyses were conducted using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA) or SPSS for windows (version 15; SPSS, Chicago, IL).

### Results

#### Characteristics of cohort at baseline

A total of 371 hemodialysis patients (246 men and 125 women) with a median age of 67 years (IQR, 57 to 75 years), a median time since initiation of dialysis of 250 days (IQR, 31 to 1122 days), and a median dialysis dose (kt/V) of 1.0 (IQR, 0.9 to 1.2) entered into the study. The cause of chronic kidney disease was hypertensive nephrosclerosis in 125 cases (34%), diabetic nephropathy in 121 cases (32%), chronic glomerular nephritis in 30 cases (8%), polycystic kidney disease in 10 cases (3%) and other/unknown in 85 cases (23%). None of the patients had Goodpasture’s syndrome, Alport-syndrome or ankylosing spondylitis.

Plasma P4NP_7S concentrations were determined as a quantitative marker for systemic collagen type IV formation in systemic fibrosis. Median plasma P4NP_7S concentrations were 387 pg/L (IQR, 293 to 594 pg/L). P4NP_7S concentrations were similar in men and women (388 pg/L; IQR, 311 to 600 pg/L; $n = 246$; vs. 387 pg/L; IQR, 267 to 575 pg/L; $n = 125$; $P = 0.247$). P4NP_7S concentrations were similar for all causes of chronic kidney disease (nephrosclerosis, 363 pg/L; IQR, 282 to 591 pg/L; diabetic nephropathy, 407 pg/L; IQR, 316 to 579 pg/L; chronic glomerular nephritis, 453 pg/L; IQR, 318 to 656 pg/L; polycystic kidney disease, 350 pg/L; IQR, 273 to 478 pg/L; other/unknown, 397 pg/L; IQR, 302 to 610 pg/L; $P = 0.521$). P4NP_7S concentrations were similar in subgroups of patients with time since initiation of dialysis less or more than 90 days (incident dialysis patients, 419 pg/L; IQR, 293 to 618 pg/L; $n = 135$; vs. prevalent dialysis patients 378 pg/L; IQR, 293 to 579 pg/L; $n = 236$; $P = 0.340$).

Table 1 summarizes clinical and laboratory variables stratified according to categories of plasma P4NP_7S concentrations. The lowest category patients had a P4NP_7S plasma concentration less than 250 pg/L, the medium category patients had concentrations between 250 and 350 pg/L, and the highest category patients had concentrations greater than 350 pg/L.

#### Table 1. Baseline clinical and biochemical characteristics of prevalent hemodialysis patients by categories of plasma concentrations of 7S domain of collagen type IV (P4NP_7S).

| Characteristic | Lowest category | Medium category | Highest category | P-value |
|----------------|-----------------|-----------------|-----------------|---------|
| Age (years)    | 65 (56 to 74)   | 67 (56 to 75)   | 67 (64 to 77)   | 0.342   |
| Gender (% Female) | 46%              | 32%             | 35%             | 0.234   |
| Time since initiation of dialysis (days) | 518 (31 to 1437) | 245 (31 to 1142) | 134 (31 to 790) | 0.344   |
| Diabetes mellitus (%) | 43%              | 38%             | 41%             | 0.900   |
| Current smoker (%) | 27%              | 31%             | 19%             | 0.278   |
| Weight (kg)    | 68 (62 to 82)   | 72 (63 to 80)   | 70 (58 to 80)   | 0.812   |
| Body mass index<sup>a</sup> (kg/m²) | 24.1 (22.3 to 27.2) | 24.6 (22.0 to 27.6) | 24.9 (20.9 to 27.0) | 0.817   |
| Systolic blood pressure (mmHg) | 131 (115 to 147) | 136 (117 to 150) | 118 (97 to 143) | 0.013   |
| Diastolic blood pressure (mmHg) | 71 (58 to 85)   | 70 (59 to 81)   | 63 (54 to 70)   | 0.016   |
| Hemoglobin (mg/dL) | 10.3 (8.6 to 11.7) | 10.2 (9.0 to 11.7) | 10.0 (9.2 to 11.0) | 0.794   |
| Leukocytes (10<sup>9</sup>/L) | 8 (5 to 11) | 8 (6 to 11) | 8 (6 to 12) | 0.641 |
| Platelets (10<sup>9</sup>/L) | 214 (140 to 290) | 231 (179 to 294) | 198 (136 to 257) | 0.056   |
| Serum albumin (g/L) | 3.5 (2.9 to 3.9) | 3.3 (2.9 to 3.7) | 3.1 (2.5 to 3.8) | 0.097   |
| Urea (mg/dL)    | 87 (61 to 119)  | 70 (52 to 99)   | 68 (45 to 84)   | 0.010   |
| Serum potassium (mmol/L) | 4.6 (4.1 to 5.5) | 4.7 (4.2 to 5.2) | 4.5 (4.0 to 5.3) | 0.535   |
| Serum calcium (mmol/L) | 2.21 (2.09 to 2.42) | 2.21 (2.08 to 2.40) | 2.21 (2.07 to 2.36) | 0.700   |
| Serum phosphorus (mg/dL) | 1.52 (1.20 to 2.10) | 1.60 (1.20 to 2.07) | 1.59 (1.09 to 2.13) | 0.850   |
| Parathyroid hormone (mg/mL) | 95 (33 to 296) | 109 (42 to 233) | 96 (52 to 191) | 0.861 |
| Serum cholesterol (mg/dL) | 178 (134 to 222) | 158 (135 to 193) | 139 (117 to 170) | 0.019   |
| Low-Density-Lipoprotein-cholesterol (mg/dL) | 112 (84 to 128) | 97 (75 to 122) | 87 (64 to 106) | 0.044   |
| High-sensitive C-Reactive-Protein (mg/dL) | 2.0 (0.4 to 4.3) | 2.7 (1.0 to 5.5) | 3.0 (1.4 to 5.6) | 0.119   |
| Dialysis dose (kt/V) | 1.13 (0.97 to 1.30) | 1.17 (1.04 to 1.33) | 1.25 (1.10 to 1.39) | 0.138   |
| Angiotensin converting enzyme inhibitors (%) | 30% | 25% | 35% | 0.376 |
| β-Blockers (%) | 54% | 62% | 46% | 0.121 |
| Calcium channel blockers (%) | 14% | 32% | 27% | 0.070 |
| Erythropoietin therapy (%) | 38% | 51% | 54% | 0.295 |

<sup>a</sup>Continuous variables are given as medians and interquartile range. Between categories, comparisons were made using non-parametric Kruskal-Wallis test for continuous variables and using Chi square test for categorical variables.

<sup>b</sup>Body mass index was calculated as weight in kilograms divided by height in meters squared.

doi:10.1371/journal.pone.0071050.t001
than 235 pg/L, the medium category had plasma P4NP_7S concentrations from 235 pg/L to 775 pg/L, and the highest category had plasma P4NP_7S concentrations higher than 775 pg/L. Hemodialysis patients with plasma P4NP_7S concentrations in the highest category had lower systolic (P = 0.013) and lower diastolic blood pressure (P = 0.016).

Hemodialysis patients with plasma P4NP_7S concentrations in the highest category also had lower urea (P = 0.010), a proxy for reduced dietary protein intake. Furthermore, serum cholesterol was significantly lower in the highest P4NP_7S category (P = 0.019) and Low-Density-Lipoprotein-cholesterol was significantly lower in the highest P4NP_7S category (P = 0.044). Reduced dietary protein intake and malnutrition is often observed in patients with chronic kidney disease [21]. On the other hand, high-sensitive C-Reactive Protein concentrations were not significantly different between the categories (P = 0.119). Time since initiation of dialysis appeared little longer in patients with the lowest category of plasma P4NP_7S concentrations, however, it should be noted that time since initiation of dialysis were not significantly different between the categories (P = 0.344). Furthermore, age, gender, dialysis dose, hemoglobin concentrations, serum calcium concentrations, serum phosphorous concentrations, and number of patients using angiotensin converting enzyme inhibitors, β-blockers, calcium channel blockers, and erythropoietin were similar in the categories.

Analysis of outcome
182 patients (49%) died during a follow up time of 5 years. Death occurred at a median of 201 days (IQR, 61 to 471 days) after study entry. The causes of death were cardiovascular diseases in 113 patients (62%), infections in 36 patients (20%), cancer in 22 patients (12%), and others/unknown in 11 (6%). In hemodialysis patients with the highest systemic collagen type IV formation an increased risk for death was observed (highest plasma P4NP_7S category vs all other categories, hazard ratio [HR], 1.934; 95% confidence interval [CI], 1.139 to 3.285, Mantel-Haenszel method). Further Kaplan-Meier analysis revealed significant survival differences between hemodialysis patients stratified into plasma P4NP_7S categories. Survival analysis showed an increased risk of death in the highest plasma P4NP_7S category compared to all other categories (Chi square 6.903; P = 0.032 by log-rank test). Median survival was only 105 days in the highest plasma P4NP_7S category, whereas it was 629 days in the medium category, and 905 days in the lowest plasma P4NP_7S category (Figure 1). In hemodialysis patients with the highest systemic collagen type IV formation the causes of death were cardiovascular diseases in 50%, infections in 34%, cancer in 8%, and others/unknown in 8%. Similar results were obtained in subgroups of patients with time since initiation of dialysis less or more than 90 days. In patients with time since initiation of dialysis less than 90 days the median survival was only 362 days in the highest plasma P4NP_7S category, whereas it was 901 days in the lowest plasma P4NP_7S category. In patients with time since initiation of dialysis more than 90 days the median survival was only 176 days in the highest plasma P4NP_7S category, whereas it was 634 days in the lowest plasma P4NP_7S category (Figure 2).

Results from univariable and multivariable-adjusted Cox regression are given in Table 2. Univariable Cox regression showed that plasma P4NP_7S category (P = 0.013), age (P < 0.001) and systolic blood pressure (P = 0.032) were associated with mortality in hemodialysis patients, whereas gender (P = 0.696),
diastolic blood pressure (P = 0.359), and urea (P = 0.176) were not associated with outcome.

Multivariable-adjusted Cox regression showed that the change in odds for death was 1.451 in higher plasma P4NP_7S category. As age is increased by one year the change in odds for death is 1.060. As systolic blood pressure is increased by one mmHg the change in odds for death is 0.988. In multivariable-adjusted Cox regression gender, diastolic blood pressure, and urea showed no effect.

### Assessment of collagen turnover

To assess extracellular matrix turnover in hemodialysis patients we also analyzed plasma concentrations of the collagen type IV degradation product C4M. We observed a significant association of P4NP_7S concentrations with C4M concentrations (Spearman r = 0.764; P < 0.001; **Figure 3**). Hemodialysis patients in the highest plasma P4NP_7S category had higher C4M concentrations (median, 180 pg/L; IQR, 147 to 218 pg/L) compared to the medium category (median, 90 pg/L; IQR, 72 to 118 pg/L) and compared to the lowest category (median, 60 pg/L; IQR, 47 to 70 pg/L; P < 0.0001). These findings suggest characteristic extracellular matrix turnover in hemodialysis patients.

### Discussion

The present study indicates that hemodialysis patients with high systemic collagen type IV formation had an increased risk for death. After multivariable adjustment higher plasma P4NP_7S concentrations and higher age increased the odds for death in hemodialysis patients. The demonstration of a significant effect of systemic collagen type IV formation on dialysis survival is novel, challenging conventional management of hemodialysis patients.

Several biological mechanisms provide a plausible explanation for the association between high plasma P4NP_7S concentrations and death in hemodialysis patients. Plasma P4NP_7S concentrations are a quantitative marker for systemic collagen type IV formation in systemic fibrosis. Chronic tissue injury with activated fibrogenesis results in disruption of tissue architecture, organ dysfunction and finally organ failure and death. A universal feature of fibrosis is the complex interplay between the inflammatory-epithelial-myofibroblast and extracellular matrix components [22]. Increased oxidative stress in hemodialysis patients establishes pathological repair leading to accumulation of permanent fibrotic scar tissue at the site of injury. In addition to increased oxidative stress, accumulation of several uremic toxins, including indoxyl sulfate, can contribute to increased systemic fibrosis in chronic kidney disease [6, 21, 23]. Increased fibrosis is mainly supported by epithelial to mesenchymal transition which describes the transdifferentiation of an epithelial cell to a cell with myofibroblast-like features. Endothelial to mesenchymal transition has been described as a potential source of activated myofibroblasts causing fibrosis in chronic kidney disease [24, 25]. This fibrosis is characterized by the excessive accumulation of extracellular matrix components including collagens [24]. Increased glycation and oxidation of collagen type IV together with increased accumulation of extracellular matrix components has been reported in chronic kidney disease. These modifications of collagen type IV lead to the detachment and loss of functional cells [26]. Our present study is the first showing that hemodialysis patients with enhanced systemic fibrosis characterized by high plasma P4NP_7S concentrations had an increased risk for death. Earlier studies in both healthy and elderly individuals with cardiovascular disease had also shown that plasma markers of collagen turnover are significantly associated with myocardial infarction, heart failure, and death [27].

Enhanced systemic fibrosis presenting as uremic cardiomyopathy is a characteristic feature in hemodialysis patients [28]. As reviewed by Gross & Ritz, the collagen content of the cardiac interstitium has important functional consequences in uremic cardiomyopathy. Cardiac fibrosis is an important determinant for left ventricular compliance, systolic stress-strain relationship and local inhomogeneities of electrical resistance [5]. Murakami et al. demonstrated elevated collagen type IV transcripts in the infarct zone of rat myocardial infarction, suggesting that type IV collagen contributes to the pathological response after myocardial injury [29]. In line with these observations, Herzog et al. reported poor long-term survival after acute myocardial infarction among...
hemodialysis patients [30]. According to our present study the identification of hemodialysis patients with high plasma P4NP_7S concentrations may help to uncover patients with increased risk for death due to systemic fibrosis. Such measurements may be advantageous with the advent of novel therapeutic strategies for systemic fibrosis [31,32]. Furthermore, enhanced vascular fibrosis may also contribute to the observed increased risk for death with high systemic collagen type IV formation. Both, clinical and experimental studies indicated structural changes in the vasculature associated with chronic kidney disease [33,34]. Accordingly, several authors have shown increased vascular stiffness in hemodialysis patients [35,36].

It should be noted that P4NP_7S concentrations were similar in subgroups of patients with time since initiation of dialysis less than 90 days (incident dialysis patients) or more than 90 days (prevalent dialysis patients). Time since initiation of dialysis was not significantly different between the categories of plasma P4NP_7S concentrations. Furthermore, analyses of incident and prevalent subgroups of hemodialysis patients showed similar results, i.e. for both incident and prevalent subgroups, patients in the highest plasma P4NP_7S category showed higher mortality compared to patients in the lowest plasma P4NP_7S category. However, our data may indicate that hemodialysis may accelerate systemic fibrosis. Comparing survival times in the highest plasma P4NP_7S category showed that in patients with time since initiation of dialysis less than 90 days the median survival was 362 days, whereas in patients with time since initiation of dialysis more than 90 days the median survival was only 176 days. Taken together, among hemodialysis patients elevated systemic collagen type IV formation was significantly associated with increased risk of death. This finding has implications for hemodialysis patients with regard to the mechanisms underlying elevated mortality risks and in the identification of systemic fibrosis in these patients. Determination of plasma P4NP_7S concentrations may help to uncover patients with increased risk for systemic fibrosis and death. In addition, because end-stage renal disease may be viewed as an in vivo model of accelerated systemic fibrosis, this study may have relevance for other renal and non-renal populations characterized by tissue fibrosis.

Author Contributions
Conceived and designed the experiments: DJL MAK LMR AS MT. Performed the experiments: DJL LMR AS MT. Analyzed the data: DJL MAK LMR AS MT. Contributed reagents/materials/analysis tools: DJL MAK LMR AS MT. Wrote the paper: DJL MAK LMR AS MT.

References
1. Kim H, Kim M, Kim H, Kim YL, Kang SW, et al. (2013) Early referral to a nephrologist improved patient survival: prospective cohort study for end-stage renal disease in Korea. PLoS One 8:e53523. doi: 10.1371/journal.pone.0053523.
2. Wong G, Howard K, Chapman JR, Chadban S, Cross N, et al. (2012) Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS One. 2012;7:e29591. doi: 10.1371/journal.pone.0029591.
3. Kovesdy CP, Lott EH, Lu JL, Makaukans SM, Ma JZ, et al. (2012) Hypotremoratia, hyperatemrnia, and mortality in patients with chronic kidney disease with and without conngestive heart failure. Circulation 125:677–684.
4. DeJager DJ, Grootendorst DR, Jager KJ, van Dijk PC, Tomas LJ, et al. (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302:1782–1789.
5. Gross ML, Ritz E (2008) Hypertrophy and fibrosis in the cardiomyopathy of uremia–beyond cor coronary heart disease. Semin Dial 21:308–318.
6. Miyamoto T, Carrero JJ, Stenvinkel P (2011) Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hyper 20:662–668.
7. Mohar MZ, Kesee A, Gizzi ME, Rusls A, Ujivasra A, et al. (2010) Evaluation of the malnutrition–inflammation score in kidney transplant recipients. Am J Kidney Dis 56:102–111.
8. Cho KH, Kim HJ, Rodrigoz-Urbe B, Vaziri ND (2009) Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol 297:F106–113.
9. Pohlers D, Brenmoehl J, Zoller M, Muller CK, Liepser C, et al. (2009) TGFBeta and fihrosis in different organs - molecular pathway imprints. Biochem Cell Acta 1792:746–756.
10. Semple D, Smith K, Bhardwaj S, Seymour AM (2011) Uremic cardiomyopathy and insulin resistance: a critical role for akt? J Am Soc Nephrol 22:207–215.
11. Zohy R, Hynes PJ, Vittorio TJ (2008) Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardioenal syndrome. Am J Transplant 8:2219–2224.
12. Elkaher J, Kenneth B, Yasashi B, Vetterl S, Shlyak A, et al. (2007) Maribulosagin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49:215–224.
13. Keller F, Lyreal Y, Schuppab D (1992) Raised concentrations of the carboxy terminal propeptide of type IV (basement membrane) procollagen (NC1) in seminal and urine of patients with gonospermoluphy. Eur J Clin Invet 22:175–181.
14. Dixit SN, Smart JR, Seyer JR, Risteli J, Timpl R, et al. (1981) Type IV collagens’ isolation and characterization of 7S collagen from human kidney, liver and lung. Coll Relat Res 13:545–556.
15. Kartunen T, Risteli J, Autio-Harimann R, Risteli L (1986) Effect of age and diabetes on type IV collagen and laminin in human kidney cortex. Kidney Int 30:586–591.
16. Vlomen LJ, Baadle JJ, Westendorp RG, Dahl MR, van Es LA, et al. (1995) Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the intestinal extracellular matrix. Clin Nephrol 44:211–219.
17. Araki S, Haneza M, Koyda D, Ishiki K, Kame S, et al. (2010) Association between urutine type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 33:1805–1810.
18. Morita M, Uchigita Y, Hanai K, Ogawa Y, Iwamoto Y (2011) Association of urinary type IV collagen with GFR decline in young patients with type 1 diabetes. Am J Kidney Dis 58:915–920.
19. Leeming DJ, Nielsen MJ, DAI Y, Verdi SS, Vassiladi P, et al. (2012) Enzyme-linked immunosorbent assay specific for the 7S domain of collagen type IV (P4NP7S): A marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res 42:482–493.
20. Niemela O, Risteli L, Sotaniemi EA, Stenback F, Ristikj J (1988) Serum antigens reflecting basement membrane and type III procollagen metabolism in primary biliary cirrhosis. J Hepatol 6:307–314.
21. Himmelfarb J, Stenvinkel P, Rizker TA, Hakim RM (2002) The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1258–1330.
22. Henderson NC, Scherphof GD (2012) Integrin-mediated regulation of TGF(β) in fibrosis. Biochim Biophys Acta. doi: 10.1016/j.bbadis.2012.10.005. [Epub ahead of print]
23. Lekawaniyit S, Kompa AR, Mame M, Wang BH, Langham GR, et al. (2012) Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One. 7:e11291.
24. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrogenic therapeutic translation for fibrotic disease. Nat Med 18:1029–1040.
25. Zeudling M, Duffellos JS (2010) Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 21:1247–1253.
26. Thomasley PJ, Rabbani N (2011) Protein damage in diabetes and uremia–identifying hotspots of protosome damage where minimal modification is amplified to marked pathophysiological effect. Free Radic Res 45:89–100.
27. Barasch E, Gottleder JS, Aurigemma G, Kitzman DW, Han J, et al. (2011) The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ Heart Fail 4:733–739.
28. Lois MA, Memoli B, Contaidi C, Barbati G, Del Prete M, et al. (2010) Myocardial fibrosis and diastolic dysfunction in patients on chronic haemodiagnosis. Nephrol Dial Transplant 25:1950–1954.
29. Murakami M, Kaishchi S, Nakahama M, Naito I, Murakami T, et al. (1998) Expression of the alpha 1 and alpha 2 chains of type IV collagen in the infarct zone of rat myocardial infarction. J Mol Cell Cardiol 30:799–805.
30. Herzog CA, Ma JZ, Collins AJ (1998) Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799–805.
31. Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106:1675–1680.
32. Gu HP, Lin S, Xu M, Yu HY, Du XJ, et al. (2012) Up-regulating relaxin expression by Gq-xquadruplex interactive ligand to achieve antifibrotic action. Endocrinology 153:3692–3700.
33. Briet M, Burns KD (2012) Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin Sci (Lond) 123:399–416.
34. Törnig J, Amann K, Ritz E, Nichols C, Zeier M, et al. (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effect of Ramipril, Nifedipine and Moxonidine. J Am Soc Nephrol 7: 667–675.
35. Scholze A, Thies C, Cheikhalfraj M, Wittstock A, Pommer W, et al. (2009) Mortality risk in hemodialysis patients with increased arterial stiffness is reduced by attainment of classical clinical performance measures. Am J Nephrol 29:598–606.
36. Briet M, Pierre B, Laurent S, London GM (2012) Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 82:888–900.